ALK-Abelló A/S·Healthcare

ALK-Abelló A/S (AKBLF) Shareholder/Analyst Call Transcript

ALK-Abelló A/S (AKBLF) Q4 2025 Earnings Call Transcript

ALK (ALKB:DC / OMX: ALK B) will publish its annual report for 2025 in the morning on Friday, 20 February 2026. Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m.
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.